The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RGNX | +39.52% | -78.16% | -26.22% | -71% |
| S&P | +16.91% | +77.79% | +12.19% | +243% |
Regenxbio is the expert in adeno-associated virus (AAV) delivery of potentially curative gene therapies through its NAV technology platform.
The company focuses on using its technology for gene-editing therapies.
Now is a good time to take a closer look at these stocks.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $30.34M | 43.0% |
| Gross Profit | $24.41M | 124.5% |
| Gross Margin | 80.46% | 29.2% |
| Market Cap | $728.97M | 90.3% |
| Market Cap / Employee | $2.07M | 0.0% |
| Employees | 353 | 0.0% |
| Net Income | -$67,149.00K | -31.2% |
| EBITDA | -$48,525.00K | 16.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $34.47M | -40.1% |
| Accounts Receivable | $25.35M | 7.4% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $147.41M | 48.1% |
| Short Term Debt | $47.90M | 13.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -42.19% | 1.5% |
| Return On Invested Capital | -37.25% | -8.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$56,451.00K | -38.1% |
| Operating Free Cash Flow | -$55,960.00K | -38.0% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.36 | 1.50 | 2.28 | 4.51 | 255.40% |
| Price to Sales | 4.60 | 2.35 | 2.71 | 3.09 | -51.07% |
| Price to Tangible Book Value | 1.36 | 1.50 | 2.28 | 4.51 | 255.40% |
| Enterprise Value to EBITDA | -6.13 | 14.51 | -6.25 | -10.15 | 39.43% |
| Return on Equity | -47.4% | -62.5% | -76.9% | -107.0% | 34.61% |
| Total Debt | $133.53M | $271.69M | $268.14M | $195.30M | 37.81% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
